Genkyotex

Switzerland
Hasle, Lucerne, Switzerland, CH-1228

Company profile

Genkyotex company profile

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Business identity

Contact email
[email protected]
Phone number
141228801013
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2006-01-01, Year

Headquarters

Postal code
CH-1228
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
8
Total equity funding
$87.1M
Last funding
Post IPO Equity / $5.4M / 2020-02-06
Last equity funding
Post IPO Equity / $5.4M
Investors
10
Lead investors
3
Founders
1
Articles
24
Exited on
2014-04-11

Founders and investors

Founders

Philippe Wiesel

Lead investors

Andera PartnersNeomed ManagementSociete Generale Asset Management

Investors

Andera PartnersBioMedPartnersEdmond de Rothschild Private EquityVesalius Biocapital PartnersVI Partners